New human rabies vaccines in the pipeline

Fooks, Anthony R.; Banyard, Ashley C.; Ertl, Hildegund C.J.

doi:10.1016/j.vaccine.2018.08.039

Cited by 23 publications

(5 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To achieve these objectives, many alternative rabies vaccines are in the experimental phase of development, such as DNA and RNA based vaccines, attenuated RABV, plant-based vaccines and recombinant virus-vector vaccines [30]. To date, only a mRNA-based vaccine has PLOS NEGLECTED TROPICAL DISEASES progressed to Phase I clinical trial [31] but, despite the repeated doses, the mRNA vaccine was clearly inferior to licensed vaccines and requires further development of better optimized formulations.…”

Section: Discussionmentioning

confidence: 99%

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

Napolitano¹,

Merone²,

Abbate³

et al. 2020

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Rabies, caused by RNA viruses in the Genus Lyssavirus, is the most fatal of all infectious diseases. This neglected zoonosis remains a major public health problem in developing countries, causing the death of an estimated 25,000–159,000 people each year, with more than half of them in children. The high incidence of human rabies in spite of effective vaccines is mainly linked to the lack of compliance with the complicated administration schedule, inadequacies of the community public health system for local administration by the parenteral route and the overall costs of the vaccine. The goal of our work was the development of a simple, affordable and effective vaccine strategy to prevent human rabies virus infection. This next generation vaccine is based on a replication-defective chimpanzee adenovirus vector belonging to group C, ChAd155-RG, which encodes the rabies glycoprotein (G). We demonstrate here that a single dose of this vaccine induces protective efficacy in a murine model of rabies challenge and elicits strong and durable neutralizing antibody responses in vaccinated non-human primates. Importantly, we demonstrate that one dose of a commercial rabies vaccine effectively boosts the neutralizing antibody responses induced by ChAd155-RG in vaccinated monkeys, showing the compatibility of the novel vectored vaccine with the current post-exposure prophylaxis in the event of rabies virus exposure. Finally, we demonstrate that antibodies induced by ChAd155-RG can also neutralize European bat lyssaviruses 1 and 2 (EBLV-1 and EBLV-2) found in bat reservoirs.

show abstract

Section: Discussionmentioning

confidence: 99%

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

Napolitano¹,

Merone²,

Abbate³

et al. 2020

PLoS Negl Trop Dis

View full text Add to dashboard Cite

show abstract

“…And using the needle-free injection, the ID route performed better than the IM route (Alberer et al 2017). Yet, multiple clinical trials for the RNActive mRNA vaccines had shown moderate efficacy, such as a weaker antibody titer than available vaccines in the clinic against rabies virus (Alberer et al 2017;Fooks et al 2019) and low anti-tumor activity against several types of cancer (Rausch et al 2014;Kubler et al 2015;Sebastian et al 2019). Subsequently, their next generation of rabies mRNA vaccine delivered by LNP is being tested in a clinical trial (NCT03713086).…”

Section: Co-delivery Of Mrnas Encoding Antigens and Immunostimulatory Proteinsmentioning

confidence: 99%

Formulation and Delivery Technologies for mRNA Vaccines

Zeng

Zhang

Walker

et al. 2020

Current Topics in Microbiology and Immunology

118

131

View full text Add to dashboard Cite

mRNA vaccines have become a versatile technology for the prevention of infectious diseases and the treatment of cancers. In the vaccination process, mRNA formulation and delivery strategies facilitate effective expression and presentation of antigens, and immune stimulation. mRNA vaccines have been delivered in various formats: encapsulation by delivery carriers, such as lipid nanoparticles, polymers, peptides, free mRNA in solution, and ex vivo through dendritic cells. Appropriate delivery materials and formulation methods often boost the vaccine efficacy which is also influenced by the selection of a proper administration route. Co-delivery of multiple mRNAs enables synergistic effects and further enhances immunity in some cases. In this chapter, we overview the recent progress and existing challenges in the formulation and delivery technologies of mRNA vaccines with perspectives for future development.

show abstract

“…We note, in addition, that new rabies vaccine products are under development and may result in new recommendations for fieldworkers and others at risk for rabies exposure. 40 , 41 …”

Section: Pre- and Post-exposure Prevention And Medical Surveillance E...mentioning

confidence: 99%

Biosafety Practices When Working with Bats: A Guide to Field Research Considerations

et al. 2022

View full text Add to dashboard Cite

Introduction: Field work with bats is an important contribution to many areas of research in environmental biology and ecology, as well as microbiology. Work with bats poses hazards such as bites and scratches, and the potential for exposure to infectious pathogens such as rabies virus. It also exposes researchers to many other potential hazards inherent to field work, such as environmental conditions, delayed emergency responses, or challenging work conditions. Methods: This article discusses the considerations for a thorough risk assessment process around field work with bats, pre- and post-occupational health considerations, and delves into specific considerations for areas related to biosafety concerns—training, personal protective equipment, safety consideration in field methods, decontamination, and waste. It also touches on related legal and ethical issues that sit outside the realm of biosafety, but which must be addressed during the planning process. Discussion: Although the focal point of this article is bat field work located in northern and central America, the principles and practices discussed here are applicable to bat work elsewhere, as well as to field work with other animal species, and should promote careful considerations of how to safely conduct field work to protect both researchers and animals.

show abstract

New human rabies vaccines in the pipeline

Cited by 23 publications

References 83 publications

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C

Formulation and Delivery Technologies for mRNA Vaccines

Biosafety Practices When Working with Bats: A Guide to Field Research Considerations

Contact Info

Product

Resources

About